JP2024153797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024153797A5 JP2024153797A5 JP2024122919A JP2024122919A JP2024153797A5 JP 2024153797 A5 JP2024153797 A5 JP 2024153797A5 JP 2024122919 A JP2024122919 A JP 2024122919A JP 2024122919 A JP2024122919 A JP 2024122919A JP 2024153797 A5 JP2024153797 A5 JP 2024153797A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- rnai agent
- administered
- rnai
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802614P | 2019-02-07 | 2019-02-07 | |
| US62/802,614 | 2019-02-07 | ||
| US201962853659P | 2019-05-28 | 2019-05-28 | |
| US62/853,659 | 2019-05-28 | ||
| US201962932315P | 2019-11-07 | 2019-11-07 | |
| US62/932,315 | 2019-11-07 | ||
| PCT/US2020/017264 WO2020163747A1 (en) | 2019-02-07 | 2020-02-07 | Rnai agents for hepatitis b virus infection |
| JP2021546213A JP7585214B2 (ja) | 2019-02-07 | 2020-02-07 | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546213A Division JP7585214B2 (ja) | 2019-02-07 | 2020-02-07 | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024153797A JP2024153797A (ja) | 2024-10-29 |
| JP2024153797A5 true JP2024153797A5 (cg-RX-API-DMAC10.html) | 2024-12-18 |
| JP7763907B2 JP7763907B2 (ja) | 2025-11-04 |
Family
ID=69771180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546213A Active JP7585214B2 (ja) | 2019-02-07 | 2020-02-07 | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 |
| JP2024122919A Active JP7763907B2 (ja) | 2019-02-07 | 2024-07-30 | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546213A Active JP7585214B2 (ja) | 2019-02-07 | 2020-02-07 | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 |
Country Status (16)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115957337A (zh) | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| TWI872048B (zh) * | 2019-02-07 | 2025-02-11 | 美商艾羅海德製藥公司 | 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑 |
| EP4168547A1 (en) * | 2020-06-22 | 2023-04-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis d virus infection |
| WO2022078479A1 (en) * | 2020-10-16 | 2022-04-21 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| TW202245809A (zh) * | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| KR102798766B1 (ko) * | 2020-12-18 | 2025-04-23 | 올릭스 주식회사 | HBV 발현을 억제하는 RNAi 제제 및 이의 용도 |
| WO2022152869A1 (en) * | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| CN117616121A (zh) * | 2021-07-09 | 2024-02-27 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 寡核苷酸用于具有肾脏损伤的个体的用途 |
| KR20240111795A (ko) * | 2021-11-29 | 2024-07-17 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법 |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| AU2025205193A1 (en) * | 2024-07-08 | 2026-01-29 | Hangzhou Tianlong Pharmaceutical Co., Ltd. | Double-Stranded RNAi Agents For Targeting And Regulating HBV Gene Expression, And A Use Thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| CN115957337A (zh) * | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| JOP20190015A1 (ar) * | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| TWI872048B (zh) * | 2019-02-07 | 2025-02-11 | 美商艾羅海德製藥公司 | 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑 |
-
2020
- 2020-02-07 TW TW109103911A patent/TWI872048B/zh active
- 2020-02-07 PH PH1/2021/551866A patent/PH12021551866A1/en unknown
- 2020-02-07 MX MX2021009495A patent/MX2021009495A/es unknown
- 2020-02-07 ES ES20709945T patent/ES3070588T3/es active Active
- 2020-02-07 EP EP20709945.8A patent/EP3920884B1/en active Active
- 2020-02-07 EP EP26151608.2A patent/EP4707394A3/en active Pending
- 2020-02-07 BR BR112021015361-6A patent/BR112021015361A2/pt unknown
- 2020-02-07 CN CN202080013136.XA patent/CN113507920A/zh active Pending
- 2020-02-07 KR KR1020217028342A patent/KR20210130736A/ko not_active Ceased
- 2020-02-07 WO PCT/US2020/017264 patent/WO2020163747A1/en not_active Ceased
- 2020-02-07 JP JP2021546213A patent/JP7585214B2/ja active Active
- 2020-02-07 CA CA3129261A patent/CA3129261A1/en active Pending
- 2020-02-07 SG SG11202108395SA patent/SG11202108395SA/en unknown
- 2020-02-07 AU AU2020219355A patent/AU2020219355A1/en not_active Abandoned
-
2021
- 2021-08-01 IL IL285257A patent/IL285257A/en unknown
- 2021-08-03 JO JOP/2021/0208A patent/JOP20210208A1/ar unknown
- 2021-08-06 US US17/396,378 patent/US20210395745A1/en active Pending
-
2024
- 2024-07-30 JP JP2024122919A patent/JP7763907B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7625637B2 (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| JP7763907B2 (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| Galbraith et al. | Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey | |
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2021500025A5 (cg-RX-API-DMAC10.html) | ||
| KR101975915B1 (ko) | 올리고뉴클레오타이드 킬레이트 복합체 방법 | |
| JP2025096283A5 (cg-RX-API-DMAC10.html) | ||
| JP2024544532A5 (cg-RX-API-DMAC10.html) | ||
| JP2025500860A5 (cg-RX-API-DMAC10.html) | ||
| HK1231402A1 (zh) | 治疗b型肝炎和d型肝炎病毒感染的方法 | |
| JP2023550061A (ja) | オリゴヌクレオチド及びその抗ｂ型肝炎とｄ型肝炎ウイルスにおける応用 | |
| JP2024527380A5 (cg-RX-API-DMAC10.html) | ||
| CN114057816B (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| JP2024528659A5 (cg-RX-API-DMAC10.html) | ||
| JP2012056896A (ja) | 難治性ウイルス感染症の治療剤 | |
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| OA19470A (en) | RNAi agents for hepatitis B virus infection. | |
| BR122025017206A2 (pt) | Agente de rnai para inibir a expressão de um gene do vírus da hepatite b (hbv), composição compreendendo o mesmo e usos do mesmo para tratar infecção crônica por hbv | |
| EA044937B1 (ru) | АГЕНТЫ РНКи ПРОТИВ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИРУСОМ ГЕПАТИТА В |